SPOTLIGHT

SPOTLIGHT CORRESPONDENCE
Imatinib mesylate induces durable complete remission of advanced CML persisting after allogeneic bone marrow transplantation Leukemia (2003) 17, 458-460. doi:10.1038/sj.leu.2402811
TO THE EDITOR
The development of imatinib mesylate (STI-571; Glivec; Gleevec; Novartis, Basel, Switzerland), a rationally designed inhibitor of the bcr-abl protein tyrosine kinase, has marked the beginning of a new era in the treatment of CML. In first chronic phase, imatinib mesylate yields complete hematological remission rates of 98% and an unprecedented 60% rate of major or complete cytogenetic responses.
1 CML in myeloid blast crisis responds substantially less well with only 8% complete hematological and 7% complete cytogenetic responses, and a high frequency of early relapses. 2 As it stands today, allogeneic stem cell transplantation remains the only established curative treatment for CML, with a 10-year disease-free survival of approximately 50% for patients in early first chronic phase and with a matched sibling donor. Allotransplanted patients with a molecular, cytogenetic or hematological relapse can often be successfully rescued by discontinuation of immunosuppressive therapy and/or infusion of donor lymphocytes (DLI). 3 Little is known on the place of imatinib mesylate in the management of disease persistence or relapse after allogeneic stem cell transplantation for CML. Here we report a case of advanced CML that persisted after a failed unrelated bone marrow transplantation. Under treatment with imatinib mesylate, stable complete donor A 30-year old man was diagnosed with with Ph-positive CML in chronic phase in December 1994. Under treatment with interferon-␣-2b, a hematological response, but no cytogenetic response, was obtained. In early 2000, a myeloid blast crisis developed, and second chronic phase was reached only after intensive therapy with etoposide, topotecan and mitoxantrone. At this advanced disease stage, it was decided to perform an allogeneic bone marrow transplantation from an unrelated male donor with an immunogenic HLA-DRB1 subtype mismatch and an HLA-DQB1 mismatch (recipient: DRB1* 1302.DRB1*1501, DQB1*0602.DQB1*0604; donor: DRB1* 1302.DRB1*1503, DQB1*0602.DQB1*0501). The patient, now 36 years old, had poorly tolerated earlier intensive chemotherapy, therefore a non-myeloablative conditioning protocol was chosen, consisting of fludarabine, busulfan and antithymocyte globulin. Posttransplant immunosuppression included cyclosporin A and short course metotrexate. Initially, G-CSF supported hematological recovery was encouraging, but discontinuation of G-CSF led to a substantial decline of the leucocyte ( Figure 1a ) and platelet counts ( Figure 1b) . In addition, analysis of peripheral blood leukocyte chimerism over this time period revealed a concomitant decrease of donor chimerism from 25% (day 33) to less than 10% (day 84). Consecutive marrow examinations revealed hypocellular marrows, with a tendency to left
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Figure 1
Evolution of peripheral blood counts, chimerism and disease burden after transplantation. (a) Leukocyte count and absolute neutrophil count. The time course of leukocyte count (WBC, black line) and absolute neutrophil count (ANC, gray line) is shown. (b) Hemoglobin level and platelet count. The time course of leukocyte count (Hb, black line) and platelet count (PLT, gray line) is shown. (c) Molecular and cytogenetic analysis of engraftment and disease burden. Peripheral blood leucocyte chimerism: Short tandem repeats (STR) and the amelogenin locus were amplified using the AmpFLSTR SGM and Profiler Plus PCR Amplification Kits (Applied Biosystems, Lennik, Belgium), according to the manufacturer's instructions. The PCR products were analyzed on the ABI 3100 genetic analyzer. For informative STRs, the height of the donor-derived allele was divided by the sum of the heights of donor and receptor alleles. The percentage donor chimerism is the average of this value for all informative STRs, multiplied by 100. The evolution of donor chimerism (left Y-axis) is shown over time (solid line, white squares). Bone marrow karyotype: Bars show the distribution of R-banded normal metaphases (gray), Ph-positive metaphases (black) and Phpositive metaphases with clonal evolution (stripes), as a function of time. The number of metaphases analyzed is given above the bar. Bcr-abl copy number in bone marrow and peripheral blood. RNA was isolated from peripheral blood or bone marrow mononuclear cells using the QIAamp Blood Kit (Qiagen, USA). cDNA synthesis (40 l) was performed using 2 g RNA, 200 units of M-MLV reverse transcriptase (Gibco BRL) and 25 M random hexamers (Amersham Pharmacia Biotech, USA). The 25 l RQ-PCR reaction mixture contained 5 l of cDNA, TaqMan Universal PCR Master Mix 2× (Applied Biosystems), 300 nM primers, 200 nM TaqMan probes as described elsewhere. 8 The detection of the PCR products was based on TaqMan technology using the ABI PRISM 7900 Sequence Detection System (Applied Biosystems, Foster City, CA, USA). A standard curve was established using a serial dilution of bcr-abl and ␤-glucuronidase plasmids (Ipsogen, Marseille, France). The copy numbers of the BCR-ABL fusion gene were normalized to those of ␤-glucuronidase, and are shown as normalized copy number (NCN, right Y-axis) as a function of time (solid dots represent bone marrow, open diamonds represent peripheral blood). The dot before transplantation represents a bone marrow sample 18 months before transplantation. In the RT-PCRs with negative results, mRNA was extracted from 3-9 × 10 6 cells. Drop lines represent day 0 (day of transplantation) and day 124 (start of imatinib mesylate).
shifting, but did not fulfil cytological critera for accelerated phase ( Table 1) . Karyotypes of these marrow aspirates continued to show almost uniform Ph positivity with additional clonal progression (46,XY, t(9;22)(q34;q11),add(17)(p11)), and with only a minority of (donor-derived) Ph-negative metaphases (Figure 1c) . Meanwhile, the patient had cutaneous and hepatic acute GVHD grade II. Therefore, neither tapering of immunosuppression nor administration of DLI were considered reasonable salvage options.
Imatinib mesylate (CSTI-571-0114 protocol, Novartis) was started on day 124 after transplantation, at an initial dose of 400 mg/day and Leukemia increased to 600 mg/day 2 weeks later. Within 6 weeks, a substantial improvement in the platelet count was observed, followed later by a more gradual increase of erythrocyte and leukocyte counts. Initially, this was accompanied by peripheral blood monocytosis and an increase in marrow monocytes and later, marrow blasts ( Figure 1a, b and Table 1 ). While these findings raised the suspicion of leukemia progression, a rapid increase of donor chimerism in the peripheral blood was found reaching 100% between days 161 and 189 (days 37 and 65 of imatinib mesylate). This complete donor chimerism has since remained stable at 100% (last measured on day 661) (Figure
SPOTLIGHT
Leukemia 1c). In addition, complete cytogenetic remission was reached in the bone marrow within 8 weeks of imatinib mesylate. Finally, the number of bcr-abl transcripts in peripheral blood, as measured by RQ-PCR, gradually declined over time, and since day 418 (day 294 of imatinib mesylate), the patient's peripheral blood has consistently tested negative on five consecutive occasions (Figure 1c ). In addition, no bcr-abl transcripts were detectable in a bone marrow aspirate on day 686 (day 562 of imanitib mesylate), indicating a disease burden of less than 1/100 000 cells in the peripheral blood and bone marrow (Figure 1c ). This molecular remission was confirmed with a nested RT-PCR (able to detect a 10 −6 dilution of cDNA of a bcr-abl-positive cell line in control cDNA) on two samples from peripheral blood (days 584 and 641) as well as a bone marrow sample (day 686) (data not shown). Except for mild facial edema, there have been no significant imatinib mesylate-related toxicities. Cutaneous GVHD and disturbed liver tests attributed to hepatic GVHD have subsided allowing discontinuation of immunosuppression after 5 months of imatinib mesylate. Presently, the patient is free from complaints, and has resumed work, as well as strenuous physical activity. The increase of central blastosis and central and peripheral monocytosis that were seen after imatinib initiation has eventually resolved ( Figure 1a, b and Table 1 ).
Thus, for this 36-year-old patient with advanced CML and medical contraindications for standard intensity conditioning, the early course after unrelated non-myeloablative transplantation was unfavorable, without sufficient engraftment of allogeneic hematopoietic stem cells and with persistence of unstable advanced CML, as indicated by a Ph-positive karyotype with clonal progression. In addition, there were contraindications against tapering of immunosuppression or therapeutic immunointervention with DLI. After the initiation of imatinib mesylate about 4 months after transplantation, complete cytogenetic and complete molecular remission was reached. In addition, graft function improved yielding improved peripheral blood counts ( Figure  1a , b and Table 1 ).
At present only limited experience has been reported with imatinib mesylate in the treatment of CML after allogeneic transplantation. There are two cases of patients relapsing after allogeneic transplantation for CML and in whom imatinib mesylate treatment induced sustained hematological and cytogenetic remission. 4, 5 Others have demonstrated that the association of imatinib mesylate and DLI can be highly effective as a treatment for Ph-positive acute leukemia relapsing after BMT. 6 Here, we report on the use of imatinib mesylate in a setting of persistent disease after allogeneic hematopoietic stem cell transplantation. There are several important observations. First, initiation of imatinib mesylate led to rapid eradication of recipient hematopoiesis, as detected by chimerism analysis on peripheral blood. Second, despite the advanced disease stage, this was followed by a complete cytogenetic response achieved in the bone marrow within 2 months after initiation of therapy. Moreover, there was a gradual decrease of the number of bcr-abl transcripts in peripheral blood, as well as in bone marrow, and a complete molecular remission (as verified with RQ-PCR and nested RT-PCR) was reached in peripheral blood as well as the bone marrow. This status of molecular remission in the peripheral blood has now been confirmed several times over a period spanning more than 250 days and it is hoped that it will be durable in the future. It is known that imatinib mesylate can induce cytogenetic remission in advanced CML. Yet, only a minority of patients with advanced CML enjoy complete cytogenetic responses or hematologic responses that are durable beyond 1 year. In addition, molecular responses to imatinib mesylate are rare in patients with chronic phase or more advanced CML.
1,2 Thus, while it cannot be excluded that the complete hematological, cytogenetic and molecular response in this patient was achieved by the sole action of imatinib mesylate, one could speculate that reduction of the disease burden by imatinib mesylate has created a window of opportunity for an alloreactive graft-versus-leukemia effect. Of note, imatinib mesylate has been reported to augment the function of antigen-presenting cells; as such it may also facilitate GVH reactivity and GVL effects. 7 Finally, despite low blood counts and peripheral blood donor chimerism at the start of imatinib, improved graft function was achieved without the need for a second infusion of donor hematopoietic stem cells.
In summary, this case indicates that imatinib mesylate can be highly efficient in treating persisting CML after allogeneic hematopoietic stem cell transplantation. The observations also suggest that imatinib mesylate may promote or synergize with the graft-versus-leukemia effect after transplantation. More data are awaited to better define the role of imatinib mesylate after allogeneic stem cell transplantation.
